You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance
|
|---|---|
| Published in |
Nature Communications, May 2017
|
| DOI | 10.1038/ncomms15159 |
| Pubmed ID | |
| Authors |
Paul M. O’Neill, Richard K. Amewu, Susan A. Charman, Sunil Sabbani, Nina F. Gnädig, Judith Straimer, David A. Fidock, Emma R. Shore, Natalie L. Roberts, Michael H.-L. Wong, W. David Hong, Chandrakala Pidathala, Chris Riley, Ben Murphy, Ghaith Aljayyoussi, Francisco Javier Gamo, Laura Sanz, Janneth Rodrigues, Carolina Gonzalez Cortes, Esperanza Herreros, Iñigo Angulo-Barturén, María Belén Jiménez-Díaz, Santiago Ferrer Bazaga, María Santos Martínez-Martínez, Brice Campo, Raman Sharma, Eileen Ryan, David M. Shackleford, Simon Campbell, Dennis A. Smith, Grennady Wirjanata, Rintis Noviyanti, Ric N. Price, Jutta Marfurt, Michael J. Palmer, Ian M. Copple, Amy E. Mercer, Andrea Ruecker, Michael J. Delves, Robert E. Sinden, Peter Siegl, Jill Davies, Rosemary Rochford, Clemens H. M. Kocken, Anne-Marie Zeeman, Gemma L. Nixon, Giancarlo A. Biagini, Stephen A. Ward |
| Abstract |
K13 gene mutations are a primary marker of artemisinin resistance in Plasmodium falciparum malaria that threatens the long-term clinical utility of artemisinin-based combination therapies, the cornerstone of modern day malaria treatment. Here we describe a multinational drug discovery programme that has delivered a synthetic tetraoxane-based molecule, E209, which meets key requirements of the Medicines for Malaria Venture drug candidate profiles. E209 has potent nanomolar inhibitory activity against multiple strains of P. falciparum and P. vivax in vitro, is efficacious against P. falciparum in in vivo rodent models, produces parasite reduction ratios equivalent to dihydroartemisinin and has pharmacokinetic and pharmacodynamic characteristics compatible with a single-dose cure. In vitro studies with transgenic parasites expressing variant forms of K13 show no cross-resistance with the C580Y mutation, the primary variant observed in Southeast Asia. E209 is a superior next generation endoperoxide with combined pharmacokinetic and pharmacodynamic features that overcome the liabilities of artemisinin derivatives. |
X Demographics
The data shown below were collected from the profiles of 32 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 14 | 44% |
| United States | 3 | 9% |
| Belgium | 1 | 3% |
| Cameroon | 1 | 3% |
| Japan | 1 | 3% |
| France | 1 | 3% |
| Unknown | 11 | 34% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 20 | 63% |
| Scientists | 9 | 28% |
| Science communicators (journalists, bloggers, editors) | 3 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 110 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| China | 1 | <1% |
| Unknown | 109 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 25 | 23% |
| Student > Ph. D. Student | 15 | 14% |
| Student > Master | 14 | 13% |
| Student > Bachelor | 11 | 10% |
| Lecturer | 6 | 5% |
| Other | 17 | 15% |
| Unknown | 22 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 28 | 25% |
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 13% |
| Agricultural and Biological Sciences | 11 | 10% |
| Biochemistry, Genetics and Molecular Biology | 10 | 9% |
| Medicine and Dentistry | 8 | 7% |
| Other | 9 | 8% |
| Unknown | 30 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 104. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 September 2019.
All research outputs
#380,529
of 24,294,766 outputs
Outputs from Nature Communications
#6,177
of 51,827 outputs
Outputs of similar age
#8,244
of 317,254 outputs
Outputs of similar age from Nature Communications
#166
of 1,051 outputs
Altmetric has tracked 24,294,766 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 51,827 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 56.2. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,254 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 1,051 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.